LAG3 and melanoma: In a Phase I/II study (NCT0198609) evaluating the safety and efficacy of anti-LAG-3 antibody in combination with anti-PD-1 antibody, 61 melanoma patients in a Phase I/II study well tolerated with an ORR of 11.5%.